Long-Term Efficacy of Psilocybin-Assisted Psychotherapy for Cancer-Related Depression: A Two-Year Follow-Up Study

Long-Term Efficacy of Psilocybin-Assisted Psychotherapy for Cancer-Related Depression: A Two-Year Follow-Up Study

Long-Term Efficacy of Psilocybin-Assisted Psychotherapy for Cancer-Related Depression: A Two-Year Follow-Up Study

Team collaborating on financial reports with graphs and laptop in modern office.
Photo by Yan Krukau on Pexels

A recent phase 2 clinical trial published in Cancer offers compelling evidence regarding the long-term efficacy of psilocybin-assisted psychotherapy in treating major depressive disorder (MDD) among cancer patients. The study, conducted by researchers at Sunstone Therapies and colleagues, followed 30 participants with cancer and MDD for two years after a single dose of psilocybin combined with psychological support.

The results demonstrate significant and sustained improvements in both depression and anxiety levels. A substantial portion of participants experienced a marked reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Specifically, 53.6% (15 of 28) showed a significant reduction in depression scores (average −15.0 points from baseline), with 50% (14 of 28) maintaining this improvement at the two-year mark. Similarly, anxiety reduction, assessed using the Hamilton Anxiety Rating Scale (HARS), was observed in 46.4% (13 of 28) of participants, with 42.9% (12 of 28) exhibiting sustained relief after two years.

Lead researcher Dr. Manish Agrawal highlighted the potential for long-term benefits, stating that a single psilocybin-assisted therapy session can provide lasting relief from depression for a significant number of cancer patients. Further research is planned to investigate the effects of repeated treatment to potentially increase the percentage of patients achieving remission. It’s important to note that several authors declared affiliations with Sunstone Therapies.

This study provides valuable insights into the potential of psilocybin-assisted psychotherapy as a novel treatment modality for cancer-related depression. The sustained improvements observed over two years suggest a lasting impact, warranting further investigation and exploration of its potential role in broader clinical practice. However, it is crucial to acknowledge the limitations of a relatively small sample size and the need for larger, more comprehensive studies to confirm these findings and explore optimal treatment protocols.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.

Comments are closed.